Company intelligence / Profile preview

Promaxo

Oakland, California, United Statespromaxo.com ↗

Ownership: Private
Development stage: Commercial

Overview

Promaxo has developed a proprietary office-based, single-sided portable MRI system that received FDA 510(k) clearance in March 2021. The system enables live MR image-guided biopsies and interventions, primarily targeting prostate cancer care. Clinical validation supports its use for improved diagnostic confidence and treatment precision in office settings. The company is commercializing this technology in the urology market with plans for expansion into additional verticals.

Therapeutic areas: OncologyNeurology
Modalities: DeviceRobotic systemArtificial intelligence (AI)
Industry: Medical Imaging

Partnerships

MicroPort (strategic partner/investor)Zepp Health / Huami (NYSE-listed strategic partner/investor)Kineticos Life Sciences/Kineticos Disruptor Fund (investor & commercialization support)

Beyond the preview

Go deeper on Promaxo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promaxo.

Explore the full profile